Correction: Structure-based design, optimization, and evaluation of potent stabilized peptide inhibitors disrupting MTDH and SND1 interaction (Journal of Medicinal Chemistry (2022) 65:18 (12188-12199) DOI: 10.1021/acs.jmedchem.2c00862)

Hailing Chen, Meimiao Zhan, Jianbo Liu, Zhihong Liu, Minhong Shen, Fenfang Yang, Yibin Kang, Feng Yin, Zigang Li

Research output: Contribution to journalComment/debatepeer-review

Abstract

Page 12198. Instead of The authors declare no competing financial interest , the following Note should be included: The authors declare the following competing financial interest(s): Y.K. is a founder and equity holder of Firebrand Therapeutics, Inc, which is developing inhibitors against MTDH/SND1. Received.

Original languageEnglish (US)
Pages (from-to)7668
Number of pages1
JournalJournal of Medicinal Chemistry
Volume66
Issue number11
DOIs
StatePublished - Jun 8 2023

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'Correction: Structure-based design, optimization, and evaluation of potent stabilized peptide inhibitors disrupting MTDH and SND1 interaction (Journal of Medicinal Chemistry (2022) 65:18 (12188-12199) DOI: 10.1021/acs.jmedchem.2c00862)'. Together they form a unique fingerprint.

Cite this